An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus
A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 152 participants.
Also called NCT02324491
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 152 participants
- Sponsor
- Zafgen, Inc.
- Registry
-
NCT02324491
-
- Other papers using this trial's data
- Efficacy and safety of methionine aminopeptidase 2 inhibition in type 2 diabetes: a randomised, placebo-controlled clinical trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Australia
- Registry status
- Terminated
Technical summary
Registry record NCT02324491. Randomized; triple masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2015-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus
- Condition
- Obesity
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- ZGN-440 for Injectable Suspension
- Intervention (Drug)
- ZGN-440 Placebo for Injectable Suspension
- Lead sponsor
- Zafgen, Inc.
Record details
- Record id
cardio:ct-nct02324491- Content hash
9fc203ede5872a5316c4266c371a738bcccd810f2c3974d13ae769ecbdb21b0c